Stroke: Plasma tiny RNA can predict stroke risk

Although environmental and vascular risk factors are involved in the pathological process of stroke, genetic factors are also one of the causes of ischemic and hemorrhagic stroke risk.
studies have shown that not only encode genes, especially 12q24.2 and ABO isos, account for a portion of the genetic risk, but non-coding areas of the genome, such as microRNAs, can also play a role in pathophysiology in stroke.
to better understand the role of miRNAs in stroke development and its potential as biomarkers in disease diagnosis, and to identify individuals with high-risk characteristics at an early stage.
miRNAs ≈ small non-coding RNA molecules with 22 nucleotides that regulate transcriptional gene expression by complementing the target transcript.
they can potentially target hundreds to thousands of genes and participate in various molecular pathways.
in addition to being able to regulate cellular processes in both disease and non-disease conditions, miRNAs are also released from cells into body fluids, such as plasma.
these circulatory miRNAs are very stable in the plasma, and because they are packaged into membrane gadgets, including implants, they have potential clinical significance as biomarkers of the disease.
previous studies have linked changes in plasma miRNA levels to cardiovascular disease and stroke.
most stroke-related miRNAs are cross-identified in the queue of acute stroke patients, making it uncertain whether the identified miRNAs are associated with the risk of stroke.
forward-looking queues can overcome this limitation.
fact, a recent longitudinal study with a small sample size (n-51 cases) found an average follow-up time of 2.5±1.6 years, with a link between plasma levels at miR-656-3p and miR-941 and stroke events.
, longitudinal studies of relatively long follow-up times are limited.
with this, Michelle M.J. Mens of the University of Rotterdam in the Netherlands and others, in a population-based prospective study, determined the association between circular miRNAs and all stroke and its subtype risks over a follow-up period of nearly 10 years.
, they conducted a follow-up analysis of miRNA's presumed target gene to gain insight into the potential ways in which miRNAs might play a role in stroke.
measured the expression levels of 2,083 miRNAs in plasma samples collected between 2002 and 2005 using next-generation sequencing from 1,914 stroke-free participants in the Rotterdam study.
the participants were assessed for stroke through continuous monitoring of medical records until January 1, 2016.
the relationship between 591 well-expressed miRNAs levels in plasma and event stroke was investigated using a Cox-proportional risk regression model adjusted for age, gender and vascular risk factors.
, a stroke-type analysis was conducted to assess the established link between miRNAs and ischemic, hemorrhagic and unsolt stroke.
follow-up analysis to gain insight into the association between miRNAs' hypothetical target genes and stroke.
results showed that 138 of the 1914 participants (average age 71.5 years ±7.6 years; 57.7 per cent female) were diagnosed with new stroke during an average follow-up period of 9.7±3.2 years±
the potential mixing factors, it was found that plasma levels in three miRNAs were associated with an event stroke.
these include miR-6124 (HR=1.66, miR-5196-5p (HR1.9) and miR-4292 (HR=2.65).
silicon analysis of these miRNAs hypothetical target genes (in silico) showed that variations in several target genes were found to be associated with stroke.
importance of this study is that three specific levels of miRNAs in plasma have been found to be associated with stroke risk, suggesting that they are potential biomarkers of early detection of disease.
original origin: Mens, M.M., Heshmatollah, A., Fani, L., Ikram, M. A., Ikram, M. K., samp; Ghanbari, M. (2021). Circulatory MicroRNAs as Potential Biomarkers for Stroke Risk: The Rotterdam Study. _Stroke_, STROKEAHA-120. Freeman Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medical and are not reproduced by any media, website or individual without authorization, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here